Explore original, structured summaries for research and education.
Research profile
Abaloparatide(Tymlos)
Abaloparatide(Tymlos) is indexed as a Synthetic PTHrP analog research entry. Its current evidence category is (Tymlos), and published discussion commonly places it within Healing & Recovery. This profile summarizes identifiers and literature signals; it does not provide treatment or dosing advice.
Identity
Molecular Data
- Molecular weight
- 3,960 Da
- Chain length
- 34 amino acids
- Type
- Synthetic PTHrP analog
- Reported half-life
- ~1.7 hours
C174H299N56O49 - 41% homology to PTH(1-34), 76% homology to PTHrP(1-34)Literature map
Research indications
Osteoporosis (FDA-Approved)
- Postmenopausal Osteoporosismost effective
- Male Osteoporosismost effective
Bone Health Research
- Fracture Preventionmost effective
- Sequential Therapyeffective
Evidence-gated guidance
Dosing Protocols
A medicine-related record exists, but this profile does not yet contain an independently verified, jurisdiction-specific prescribing schedule. Use only the current authorized product label and a licensed clinician’s directions.
- Dose
- Not established on this profile
- Frequency
- Not established on this profile
- Cycle
- Not established on this profile
- Storage
- Follow the exact supplier or authorized product documentation; requirements vary by formulation
Combination risks
Interactions
Evidence status
No independently verified interaction table is available here for Abaloparatide(Tymlos). Interaction risk depends on identity, formulation, medicines, supplements, and health conditions.
Do not infer compatibility
Being listed beside another compound does not mean that combining them is safe or effective.
Evidence-informed overview
What to Expect
Evidence boundary
Research indications describe topics studied in the literature; they do not predict an individual outcome.
Clinical monitoring
Where an authorized medicinal use exists, expectations and monitoring should come from the current product label and treating clinician.
Risk overview
Side Effects & Safety
The safety profile of Abaloparatide(Tymlos) cannot be inferred from category or molecular identity alone. Research-only materials are not medicines and should not be used in humans.
Verification
Quality Checklist
- Confirm exact chemical identity, sequence, salt form, and concentration.
- Require a batch-specific certificate of analysis with named test methods and results.
- Check manufacturer, lot, expiry, tamper evidence, and documented chain of custody.
- For laboratory work requiring sterility, verify sterility and endotoxin testing separately from purity.
Clear answers
Frequently Asked Questions
Is Abaloparatide(Tymlos) approved for personal use?
An approved medicine-related record may exist, but approval depends on the exact active ingredient, product, indication, formulation, and country. Check the current local regulator and product label.
Why is no dose listed?
A dose is shown only when it has been checked against a current authoritative prescribing label. Speculative or community regimens are intentionally excluded.
Do research indications prove effectiveness?
No. They organize literature topics and evidence signals; they are not treatment recommendations or guarantees.
Source trail
References
- Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis (ACTIVE Trial)Miller PD, Hattersley G, Riis BJ, et al. · JAMA · 2016
- ACTIVExtend Trial: Abaloparatide Followed by AlendronateCosman F, Miller PD, Williams GC, et al. · Mayo Clinic Proceedings · 2017
- Phase 2 Dose-finding Study of BA058 in Postmenopausal WomenLeder BZ, O'Dea LS, Zanchetta JR, et al. · Journal of Clinical Endocrinology and Metabolism · 2015
- Profile of Abaloparatide and Its Potential in Postmenopausal OsteoporosisTella SH, Kommalapati A, Correa R · Cureus · 2017